- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
ChemAxon Announces New CEO and Head of R&D
—
BUDAPEST, Hungary, May 12BUDAPEST, Hungary, May 12 /PRNewswire/ -- ChemAxon, a software solutions provider for cheminformatics, today announced the appointment of Alex Drijver as CEO. The arrival signals the companies increased focus on business development and market position. Ferenc Csizmadia, founder and former CEO, moves to Chairman and Head of Research and Development. The new R&D position formalises the bridge between the customer base and the company's development strategy and in particular the next generation of products under launch.
Alex joins ChemAxon with over 20 years international commercial experience, most recently as CEO and CFO of ThalesNano Inc, a Budapest based manufacturer of novel microfluidic based instruments for chemical synthesis, and CFO of ComGenex, Inc., a chemistry services provider now part of Albany Molecular.
About ChemAxon
ChemAxon is a leader in providing cheminformatics software development platforms and applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. For more information please visit http://www.chemaxon.com.
Related Pharmalicensing company profiles
Related news
Related News
- ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration
- Mentice Appoints Bj
- Manpower Software Announces Integration of MAPS Healthroster & Bank Staff Management Solution (BSMS)
- Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
- French Agency Receives 10 Million Dollar Grant From the Bill & Melinda Gates Foundation to Support the Establishment of National Vaccine Advisory Committees in Africa and Asia
- Mentice Initiates Collaboration With Pieter Stella as Clinical Advisor
- Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
- Bruce Palsulich Joins Relsys International as Chief Innovation & Strategy Officer
- Chiltern Announces New Expansion in Portugal
- Nabriva Therapeutics Announces Appointment of New CEO
Latest News
- The Future of Financing Health Services in Africa
- Unique Digital Breast Screening Part of Offering by New Clinic
- Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa
- Unite's NHS Members Hold Day of Action on Wednesday, 3 December Over Pay
- Beat the Credit Crunch This Christmas With High Quality American Peanuts!
- Dynamics Group AG Publishes Research Report on Senetek
- diaDexus Receives CE Mark Certification for the PLAC(R) Test
- Improving Occupational Safety and Health Worldwide
- German Innovation for HIV/AIDS Diagnostics Has Been Used 2.5 Million Times in 2008
- Elsevier's EMBASE.com Partners With QUOSA
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us